Advice

in the absence of a submission from the holder of the marketing authorisation

saxagliptin (Onglyza®) is not recommended for use within NHS Scotland.

Indication under review: monotherapy in adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice77KB (PDF)

Download

Medicine details

Medicine name:
saxagliptin (Onglyza)
SMC ID:
958/14
Indication:
Monotherapy in adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.
Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd / AstraZeneca
BNF chapter
Endocrine system
Submission type
Non submission
Status
Not recommended
Date advice published
10 March 2014
Additional notes

The marketing authorisation for saxagliptin (Onglyza) was amended to cover use in combination with other diabetes medicines in June 2017. This minor licence change will not be assessed.